Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSLER-1: Long-term Evolocumab in Hypercholesterolemia
NCT01439880Phase 2Completed
- Sponsor
- Amgen
- Start
- Oct 2011
- Primary completion
- Jun 2018
- Modality
- Monoclonal Antibodies
- Countries
- 18
01
Overview
A Phase 2 trial of evolocumab in hypercholesterolemia, sponsored by Amgen. Started Oct 2011; status: completed.
02
Drugs
evolocumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT01439880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01439880.